Norgard Nicholas B, Badgley Brian T
University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.
Drug Healthc Patient Saf. 2010;2:163-7. doi: 10.2147/DHPS.S13239. Epub 2010 Sep 21.
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient's thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2-6 hours of eptifibatide administration.
依替巴肽是一种糖蛋白IIb/IIIa受体拮抗剂，用于降低急性冠脉综合征患者和接受经皮冠状动脉介入治疗患者的缺血事件发生率。少数接受依替巴肽治疗的患者在用药后数小时内会出现急性、严重血小板减少（<20,000个细胞/mm³）。本病例报告讨论了一名首次接受依替巴肽治疗后数小时内出现严重血小板减少的患者。Naranjo算法将该患者血小板减少与依替巴肽相关的可能性分类为很可能。严重血小板减少是依替巴肽一种罕见但具有临床重要性的并发症。本病例报告强调了在基线以及依替巴肽给药后2 - 6小时常规监测血小板计数的重要性。
